EyePoint (EYPT.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec9

Mizuho analyst maintains buy rating for Eyepoint Pharmaceuticals

16:12

Nov19

EyePoint Pharmaceuticals' DURAVYU Phase 3 Clinical Trial for Wet AMD Receives Positive Safety Review

12:06

Nov10

Mizuho Securities Maintains Buy Rating on EyePoint Pharmaceuticals

13:57

Nov7

JonesTrading Analyst Reiterates Buy Rating on EyePoint Pharmaceuticals

02:38

Nov5

EyePoint Pharmaceuticals Reports Progress on Lead Project DURAVYU, Anticipates Top-Line Phase 3 Data in Mid-2026

19:46

TD Cowen Reiterates Buy Rating With a Target Price of $20.00

17:02

Schedules & Filings

Schedules

Filings

Nov5

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 966 K, Net Income -59.73 M, EPS -0.8512

Aug6

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 5.333 M, Net Income -59.43 M, EPS -0.8498

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 24.45 M, Net Income -45.2 M, EPS -0.6477

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change